PEPG
Pepgen Inc
NASDAQ · Biotechnology
$4.48
+0.19 (+4.43%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| EPS | — | — | — |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| Rev Growth | +16.0% | +7.1% | -1.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 31.45M | 30.29M | 37.21M |
| Total Equity | 233.19M | 257.46M | 235.98M |
| D/E Ratio | 0.13 | 0.12 | 0.16 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |